Study for the effect of visceral fat reduction by SGLT2 inhibitor Ipragliglozinin patients with type 2 diabetes

Phase 4

• Conditions: type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000014058
• Lead Sponsor: Hokkaido University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-05-26
• Study Completion: 2015-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

Not provided

Exclusion Criteria

1) hypersensitivity to Ipragliflozin, 2) unstable diabetic retinopathy, 3) severe hepatic, renal, or heart dysfunction, 4) pregnancy, 5) patients who are inadequate to enter this study due to the other reasons by physician's judgments

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in visceral fat volume

Secondary Outcome Measures

Name	Time	Method
1) glucose and lipid metabolism, 2) Abdominal circumference, 3) Weight, 4) Insulin secretion and insulin resistance, 5) microalbuminuria, 6) blood test(complete blood count, electrolytes, kidney and liver function test), 7) several biomarkers (adipokines, oxidative stress, etc)